Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a large increase in short interest in February. As of February 13th, there was short interest totaling 2,466,525 shares, an increase of 82.5% from the January 29th total of 1,351,651 shares. Currently, 13.7% of the company’s stock are short sold. Based on an average trading volume of 853,907 shares, the short-interest ratio is presently 2.9 days. Based on an average trading volume of 853,907 shares, the short-interest ratio is presently 2.9 days. Currently, 13.7% of the company’s stock are short sold.

Karyopharm Therapeutics Trading Up 0.6%

Shares of KPTI stock opened at $9.41 on Monday. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $10.99. The stock has a market cap of $172.58 million, a P/E ratio of -0.57 and a beta of 0.13. The stock has a 50 day moving average of $7.59 and a 200 day moving average of $6.65.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million for the quarter, compared to analyst estimates of $33.16 million. On average, research analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KPTI has been the topic of several analyst reports. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. Royal Bank Of Canada reduced their price objective on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, November 4th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. boosted its stake in shares of Karyopharm Therapeutics by 112.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after acquiring an additional 790,417 shares in the last quarter. Ikarian Capital LLC increased its stake in shares of Karyopharm Therapeutics by 1,897.9% in the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after purchasing an additional 517,297 shares in the last quarter. Geode Capital Management LLC raised its holdings in Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares during the period. Bank of America Corp DE boosted its position in Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at approximately $1,064,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.